DR. REDDY'S LABORATORIES-ADR(NYSE:RDY) stock News

RDY Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching

14 days ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q1FY26 Financial Results

14 days ago - By: Yahoo Finance - Mentions: ALVO

Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement

2 months ago - By: Yahoo Finance - Mentions: JPM RELI OMI SMLR ...

JPMorgan Backs RIL Despite Margin Pressures

2 months ago - By: Yahoo Finance - Mentions: OMI SMLR RNXT HUM ...

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

2 months ago - By: Benzinga - Mentions: JNJ MRK ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

2 months ago - By: Zacks Investment Research - Mentions: MRK AMGN ALVO

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

2 months ago - By: Dr. Reddy’s Laboratories Ltd. - Mentions: ALVO

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

2 months ago - By: Alvotech - Mentions: ALVO SDB

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

3 months ago - By: Zacks Investment Research - Mentions: ALLO ALVO

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

3 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: TEVA

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

4 months ago - By: Yahoo Finance - Mentions: AAPL MSFT

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

4 months ago - By: Benzinga - Mentions: ARGX GILD REGN AZN ...

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

4 months ago - By: Zacks Investment Research - Mentions: JNJ AMGN ALVO

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

4 months ago - By: Bio-Thera Solutions, Ltd

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

5 months ago - By: Dr. Reddy’s Laboratories Ltd. - Mentions: ALVO

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

5 months ago - By: Alvotech - Mentions: ALVO

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

5 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

6 months ago - By: Henlius

Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA

6 months ago - By: Henlius

Henlius y Dr. Reddy's firman un acuerdo de licencia para la expansión de HLX15 en Europa y EE.UU.

6 months ago - By: Henlius

Henlius et Dr. Reddy's signent un accord de licence pour l'expansion de HLX15 (biosimilaire expérimental du daratumumab) en Europe et aux États-Unis.

6 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

6 months ago - By: Henlius

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

7 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q3 & 9MFY25 Financial Results

8 months ago - By: Dr. Reddy’s Laboratories Ltd.

DR. REDDY'S LABORATORIES-ADR (RDY) Stock News

RDY Latest News, Press Relases and Analysis

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching

Dr. Reddy’s Q1FY26 Financial Results

Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement

JPMorgan Backs RIL Despite Margin Pressures

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA

Henlius y Dr. Reddy's firman un acuerdo de licencia para la expansión de HLX15 en Europa y EE.UU.

Henlius et Dr. Reddy's signent un accord de licence pour l'expansion de HLX15 (biosimilaire expérimental du daratumumab) en Europe et aux États-Unis.

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Dr. Reddy’s Q3 & 9MFY25 Financial Results

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma